Abionyx Pharma SA
PAR:ABNX

Watchlist Manager
Abionyx Pharma SA Logo
Abionyx Pharma SA
PAR:ABNX
Watchlist
Price: 3.89 EUR Market Closed
Market Cap: 135.9m EUR

Wall Street
Price Targets

ABNX Price Targets Summary
Abionyx Pharma SA

Wall Street analysts forecast ABNX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ABNX is 10.97 EUR with a low forecast of 10.1 EUR and a high forecast of 12.08 EUR.

Lowest
Price Target
10.1 EUR
160% Upside
Average
Price Target
10.97 EUR
182% Upside
Highest
Price Target
12.08 EUR
210% Upside
Abionyx Pharma SA Competitors:
Price Targets
EXEL
Exelixis Inc
3% Upside
BIOPOR
Bioporto A/S
260% Upside
ALCLS
Cellectis SA
61% Upside
ALNY
Alnylam Pharmaceuticals Inc
8% Upside
CYTK
Cytokinetics Inc
24% Upside
DVAX
Dynavax Technologies Corp
94% Upside
214450
PharmaResearch Co Ltd
90% Upside
REGN
Regeneron Pharmaceuticals Inc
11% Upside

Revenue
Forecast

Revenue Estimate
Abionyx Pharma SA

The compound annual growth rate of Abionyx Pharma SA's revenue for the next 3 years is 61%.

N/A
Past Growth
61%
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Abionyx Pharma SA

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-22%
Average Miss

Net Income
Forecast

Net Income Estimate
Abionyx Pharma SA

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-41%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ABNX's stock price target?
Price Target
10.97 EUR

According to Wall Street analysts, the average 1-year price target for ABNX is 10.97 EUR with a low forecast of 10.1 EUR and a high forecast of 12.08 EUR.

What is Abionyx Pharma SA's Revenue forecast?
Projected CAGR
61%

The compound annual growth rate of Abionyx Pharma SA's revenue for the next 3 years is 61%.

Back to Top